# Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

> **NCT06827587** · NA · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Myasthenia Gravis
- Autoimmune Diseases
- Neuromuscular Diseases

## Interventions

- **DRUG:** Efgartigimod + Telitacicept (1-week interval) group
- **DRUG:** Efgartigimod + Telitacicept (2-week interval) group
- **DRUG:** Telitacicept-only group

## Key facts

- **NCT ID:** NCT06827587
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2026-02
- **Final completion:** 2026-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06827587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06827587, "Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06827587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*